trastuzumab deruxtecan

  • July 30, 2022  

    Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer Bookmark

    George Lundberg, MD

    Cancer that spreads to the brain is very difficult to treat, especially because of the blood-brain barrier. This article from The ASCO Post describes one promising new treatment.

    .

  • April 8, 2020  

    Tucatinib and Trastuzumab Deruxtecan Show Promise in HER2+ Breast Cancer

    Smruti Vidwans, PhD

    In 1998, the U.S. Food and Drug Administration (FDA) approved the drug trastuzumab (brand name Herceptin) for people with HER2-positive metastatic breast cancer. Overnight, HER2+ metastatic breast cancer became treatable (though not curable). Subsequent successful clinical studies led to use of trastuzumab earlier in the breast cancer journey—after surgery—to help prevent recurrence, as well as in earlier-stage HER2+ breast cancer. Meanwhile, the FDA approved… Read more »